PT2683372T - Métodos e composições para o tratamento da hiperuricemia e distúrbios metabólicos associados com a hiperuricemia - Google Patents

Métodos e composições para o tratamento da hiperuricemia e distúrbios metabólicos associados com a hiperuricemia

Info

Publication number
PT2683372T
PT2683372T PT127577674T PT12757767T PT2683372T PT 2683372 T PT2683372 T PT 2683372T PT 127577674 T PT127577674 T PT 127577674T PT 12757767 T PT12757767 T PT 12757767T PT 2683372 T PT2683372 T PT 2683372T
Authority
PT
Portugal
Prior art keywords
hyperuricemia
compositions
methods
disorders associated
metabolic disorders
Prior art date
Application number
PT127577674T
Other languages
English (en)
Inventor
Lu Wei-Shu
Sherry Ku Mannching
Chen Chih-Kuang
Lin I-Yin
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of PT2683372T publication Critical patent/PT2683372T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
PT127577674T 2011-03-11 2012-03-07 Métodos e composições para o tratamento da hiperuricemia e distúrbios metabólicos associados com a hiperuricemia PT2683372T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11

Publications (1)

Publication Number Publication Date
PT2683372T true PT2683372T (pt) 2017-10-25

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127577674T PT2683372T (pt) 2011-03-11 2012-03-07 Métodos e composições para o tratamento da hiperuricemia e distúrbios metabólicos associados com a hiperuricemia

Country Status (16)

Country Link
US (1) US8865689B2 (pt)
EP (1) EP2683372B1 (pt)
JP (1) JP6012639B2 (pt)
KR (1) KR101567885B1 (pt)
CN (1) CN103429236B (pt)
AR (1) AR085662A1 (pt)
AU (1) AU2012229443B2 (pt)
BR (1) BR112013022332A2 (pt)
CA (1) CA2829101C (pt)
ES (1) ES2634562T3 (pt)
IL (1) IL228030B (pt)
MX (1) MX350666B (pt)
PT (1) PT2683372T (pt)
RU (1) RU2603050C2 (pt)
TW (1) TWI505827B (pt)
WO (1) WO2012125359A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127240A1 (en) * 2010-04-08 2011-10-13 Twi Biotechnology, Inc. Methods of using diacerein as an adjunctive therapy for diabetes
CN103429236B (zh) 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
JP2018513203A (ja) * 2015-04-20 2018-05-24 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． ジアセレインを含有する製剤及びそれを用いて尿酸の血中濃度を低下させる方法
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
EP3316879A4 (en) 2015-07-01 2019-01-23 TWI Biotechnology, Inc. TOPICAL FORMULATIONS OF RHEINE OR DIACEREIN, AND USES THEREOF
TWI743047B (zh) 2015-08-17 2021-10-21 安成生物科技股份有限公司 使用雙醋瑞因或其類似物抑制asc表現、nlrp3表現、以及/或nlrp3發炎體複合物的形成之方法
KR101863604B1 (ko) 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
SI2124997T1 (sl) 2006-10-20 2012-11-30 Regeneron Pharma Uporaba IL antagonista za zdravljenje putike inpsevdo putike
US8821924B2 (en) * 2007-09-14 2014-09-02 Wockhardt Ltd. Rhein or diacerein compositions
WO2010003092A1 (en) 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
CN103429236B (zh) 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物

Also Published As

Publication number Publication date
ES2634562T3 (es) 2017-09-28
NZ614486A (en) 2014-11-28
IL228030A0 (en) 2013-09-30
EP2683372A1 (en) 2014-01-15
AU2012229443B2 (en) 2017-03-02
CA2829101C (en) 2019-08-20
KR20140019795A (ko) 2014-02-17
BR112013022332A2 (pt) 2017-05-30
TWI505827B (zh) 2015-11-01
CN103429236B (zh) 2016-09-21
TW201249432A (en) 2012-12-16
RU2603050C2 (ru) 2016-11-20
JP2014507476A (ja) 2014-03-27
EP2683372A4 (en) 2014-08-06
RU2013145498A (ru) 2015-04-20
JP6012639B2 (ja) 2016-10-25
EP2683372B1 (en) 2017-07-12
MX2013010384A (es) 2013-10-07
AU2012229443A1 (en) 2013-09-12
WO2012125359A1 (en) 2012-09-20
US8865689B2 (en) 2014-10-21
AR085662A1 (es) 2013-10-16
CN103429236A (zh) 2013-12-04
IL228030B (en) 2018-01-31
MX350666B (es) 2017-09-12
CA2829101A1 (en) 2012-09-20
US20120232044A1 (en) 2012-09-13
KR101567885B1 (ko) 2015-11-10

Similar Documents

Publication Publication Date Title
HK1252940A1 (zh) 用於治療無效性紅細胞生成的方法和組合物
ZA201606957B (en) Biguanide compositions and methods of treating metabolic disorders
IL228030A0 (en) Methods and compositions for the treatment of gout and gout-related metabolic disorders
HK1203830A1 (en) Compositions and methods for treating metabolic disorders
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
HK1206260A1 (en) Compositions and methods of use for treating metabolic disorders
EP2875359A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
HK1201475A1 (en) Methods and compositions for treating pain
EP2684167A4 (en) COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
PT2726099T (pt) Método para o tratamento de distúrbios metabólicos
EP2847152A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME
HK1190936A1 (zh) 治療代謝綜合徵的方法和配方
EP2766390A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEART ERRORS
TWI560523B (en) An underlayer composition and process thereof
ME02180B (me) Supstanca korisna za lečenje poremećaja metabolizma lipida
HRP20180687T1 (hr) Kompozicije i metode za liječenje celijakije spru
EP2688585A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING ANTIANGIOGEN THERAPY WITH ANTIINTEGRINES
IL235317A0 (en) A compound for the treatment of metabolic disorders
EP2557920A4 (en) METHODS FOR THE TREATMENT OF GLUCOSE METABOLISM DISORDERS
AP2013007056A0 (en) Methods and compositions for treating kidney disorders
IL229438A0 (en) Methods for treating obesity and/or metabolic syndrome
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
EP2718427A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES
EP2797948A4 (en) COMPOSITIONS AND METHODS FOR THE REGULATION OF GLUCOSE METABOLISM
EP2714082A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN